Observational study about the prognostic implication of chromosomal and genetic alterations in adult acute myeloid leukemia. -JALSG AML209 Genetic Study (AML209-GS)-

Observational study about the prognostic implication of chromosomal and genetic alterations in adult acute myeloid leukemia. -JALSG AML209 Genetic Study (AML209-GS)- - Observational study about the prognostic implication of chromosomal and genetic alterations in adult acute myeloid leukemia.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003432

Enrollment

1500

Registered

2010-04-01

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult acute myeloid leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Untreated AML patients except for APL. (2) The patients who will be received the chemotherapy for obtaining the cure of AML. (3) The patients with Performance status grade (ECOG) 0,1,2 or 3. (4) The patients with the chemotherapy tolerable liver, kidney, lung and cardiac functions. (5) The patients from whom the informed consent for the chemotherapy have been obtained.

Exclusion criteria

Exclusion criteria: 1. The patients who had received chemotherapy, irradiation or hematopoietic stem cell transplantation against acute leukemias of ambiguous lineage, myeloproliferative neoplasms, myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. 2. The patients with natural killer cell lymphoblastic leukemia / lymphoma. 3. The patients with active cancer. 4. The patients who developed myocardial infarction within 1 year. 5. The patients with diabetes which is uncontrollable even with insulin. 6. The patients with active infection. 7. The patients with liver cirrhosis. 8. The patients who have the past history of renal dysfunction. 9. The patients with deep vein thrombosis requiring the treatment. 10. The patients with psychological disease. 11. The women who is or may be in pregnancy. 12. The HBV antigen or HIV antibody positive patients.

Design outcomes

Primary

Measure	Time frame
Disease-free survival in each genotype.	—

Countries

Japan

Contacts

Public ContactKiyoi Hitoshi

Nagoya University Hospital Department of Hematology

kiyoi@med.nagoya-u.ac.jp052-744-2136

Outcome results